Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
ID: 357004Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357004

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-25-205.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in non-malignant hematology. This initiative invites investigator-initiated research project grant applications (R01) that focus on basic and early translational hematology research, with a particular emphasis on fostering diverse perspectives within research teams through a required Plan for Enhancing Diverse Perspectives (PEDP). Approximately $2.5 million is available for 5-8 awards, with applications due by February 5, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-25-205-Full-Announcement.html
    Please provide the text you would like summarized.
    PAS-25-205.html
    The National Institutes of Health (NIH) is issuing a Notice of Funding Opportunity (NOFO) titled "Stimulating Hematology Investigation: New Endeavors (SHINE)," promoting research in non-malignant hematology relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Heart, Lung, and Blood Institute. This initiative invites investigator-initiated research project grant applications (R01) focusing on innovative areas within basic and early translational hematology research. Key components of the funding include the requirement for a Plan for Enhancing Diverse Perspectives (PEDP), aimed at fostering inclusivity within research teams. Approximately $2.5 million is allocated for 5-8 awards, with applications due by February 5, 2025, for new projects. Applicants must comply with specific registration processes, and proposals will be evaluated based on scientific merit, innovation, rigor, investigator expertise, and the effectiveness of diversity plans. The SHINE program's dynamic nature allows for evolving research topics, responding to emerging questions within the hematology field, guided by workshops and public meetings. Overall, this NOFO emphasizes NIH’s commitment to innovative research and inclusivity in the scientific community.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a Limited Competition Funding Opportunity titled "Physician Scientist Transition to Independence in Blood Science Research" (R00 - Clinical Trial Optional). This initiative aims to support the transition of outstanding blood science researchers with clinical doctorate degrees from mentored research positions to independent faculty roles, providing up to three years of funding for innovative research in blood science. The program is particularly focused on enhancing the scientific workforce by promoting diversity and fostering independent research careers that address critical health challenges in hematology. Interested applicants must submit their proposals by March 28, 2025, with a total funding ceiling of $250,000 available for new awards, and can direct inquiries to grantsinfo@nih.gov for further information.
    Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity" (RFA-HG-23-017), aimed at promoting health equity through innovative genomic research. This initiative encourages applicants to propose research that enhances the understanding and application of genomics across diverse U.S. populations, with a particular focus on engaging underrepresented groups and incorporating a Plan for Enhancing Diverse Perspectives (PEDP). The NIH plans to commit significant funds, with a maximum budget of $500,000 in direct costs per year for projects lasting four to five years, and applications are due by July 8, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.
    Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the continuation of the NIDDK Hematology Central Coordinating Center (HCCC) through a cooperative agreement, aimed at enhancing collaboration among up to five Cooperative Centers of Excellence in Hematology. The HCCC will provide essential administrative and communication support, manage a Pilot and Feasibility Program, and promote research addressing nonmalignant hematologic diseases and normal hematopoiesis. This initiative is crucial for invigorating the field of hematology, fostering partnerships, and ensuring diverse perspectives in research teams. Interested applicants can find more information and apply by March 18, 2025, with an estimated funding amount of up to $1,000,000. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html.
    Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a federal grant opportunity titled "Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)." This program aims to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce by providing research experiences and related opportunities for individuals from underrepresented groups. The initiative is crucial for addressing health disparities in cardiovascular, pulmonary, and hematologic diseases by fostering a diverse scientific workforce. Interested applicants can apply for funding up to $175,000 per year for a maximum of five years, with applications opening on December 29, 2023, and a submission deadline of August 19, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-001.html.
    Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)." This initiative aims to support new investigators from diverse and underrepresented backgrounds in biomedical research, enabling them to conduct small-scale projects that align with the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other participating institutes. The grants, with a maximum budget of $125,000 per year for a project period not exceeding three years, are intended to facilitate the transition of these researchers toward independence while addressing health disparities. Interested applicants must demonstrate that they have had less than $125,000 in direct costs from combined active research funding and can submit proposals starting in early 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-097.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NIAID and NIDDK Research Opportunities for New and 'At-Risk' Investigators to Promote Workforce Diversity," aimed at enhancing diversity within the biomedical and public health research sectors. This grant supports research projects from New Investigators—those who have not previously secured substantial independent NIH funding—and At-Risk Investigators, who face potential funding loss, particularly from underrepresented backgrounds in health-related sciences. The initiative emphasizes the importance of diverse perspectives in addressing health disparities and requires applicants to demonstrate a commitment to diversity, equity, inclusion, and accessibility in their proposals. Applications are open until September 7, 2025, with no budget limits specified, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-275.html.
    Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Supporting Talented Early Career Researchers in Genomics," aimed at supporting innovative research projects led by Early Stage Investigators (ESIs) with a focus on genomics. This initiative encourages diverse applicants to propose research that aligns with the mission of the National Human Genome Research Institute (NHGRI), covering areas such as genomic sciences, genomic medicine, genomic data science, and the ethical implications of genomics. The program has a funding commitment of at least $2 million, with plans to award 3-5 grants, each with an annual budget cap of $400,000. Applications must be submitted electronically by February 26, 2027, and should include a detailed professional development plan and a resource sharing plan in compliance with NIH policies. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.